GPC3-T2-CAR-T

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameGPC3-T2-CAR-T
Drug Alias Nameanti-GPC3 CAR T-cell therapy (Second Affiliated Hospital of Guangzhou Medical University)GPC3-T2-CAR-T
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionGlypican-3 modulators
TargetsGlypican-3
Therapy Area/IndicationsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSecond Affiliated Hospital Of Guangzhou Medical University
China Registration ClassN/A

Develop Information

Active CompaniesSecond Affiliated Hospital Of Guangzhou Medical University
Inactive CompaniesN/A
Active IndicationsCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A